SCHEMBL3703700

SCHEMBL3703700

C[C@@]1(O)[C@H](O)[C@@H](COP(=O)(O)O)O[C@H]1c1ccc2c(N)ncnn12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLRMT O00411 1/20 0.45
P2RY2 P41231 2/20 0.40
DNPH1 O43598 1/20 0.40
PRKAB2 O43741 1/20 0.40
TRPM2 O94759 1/20 0.40
LDHA P00338 1/20 0.40
ADRB2 P07550 1/20 0.40
FBP1 P09467 1/20 0.40
SRC P12931 1/20 0.40
ADORA1 P30542 1/20 0.40
P2RY1 P47900 1/20 0.40
PRKAG1 P54619 1/20 0.40
PRKAA2 P54646 1/20 0.40
PDE4D Q08499 1/20 0.40
KCNH2 Q12809 1/20 0.40
PRKAA1 Q13131 1/20 0.40
PDE3A Q14432 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3696204 0.93 POLRMT (0.52) POLRMTP2RY2P2RY1P2RY4RNASEL
SCHEMBL3699139 0.91 POLRMT (0.55) POLRMTP2RY2SRCP2RY1SMN1; SMN2
SCHEMBL13519829 0.91 POLRMT (0.55) POLRMTP2RY2SRCP2RY1SMN1; SMN2
SCHEMBL16710862 0.91 POLRMT (0.55) POLRMTP2RY2SRCP2RY1SMN1; SMN2
SCHEMBL12253963 0.85 DNPH1 (0.41) P2RY2DNPH1PRKAB2TRPM2LDHA
SCHEMBL7600077 0.84 RNASEL (0.36) POLRMTRNASEL
SCHEMBL2722884 0.83 ADORA2A (0.46) POLRMTADORA1
SCHEMBL17109576 0.83 ADORA2A (0.46) POLRMTADORA1
SCHEMBL13695331 0.83 ADORA2A (0.46) POLRMTADORA1
SCHEMBL646134 0.83 ADORA2A (0.46) POLRMTADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415309-B2 Bicyclic nucleosides and nucleotides as therapeutic agents BIOTA SCIENTIFIC MANAGMENT PTY LTD (AT) 2013-04-09 US claimed
US-20120122811-A1 BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2012-05-17 US claimed
US-8415309-B2 Bicyclic nucleosides and nucleotides as therapeutic agents BIOTA SCIENTIFIC MANAGMENT PTY LTD (AT) 2013-04-09 US disclosed
US-20120122811-A1 BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122811-A1 BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS NTPCR, PNP, DCTD POLRMT 54/4885P2RY2 202/4885DNPH1 930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.